| Date | Time | Source | Headline | Symbol | Company |
| 12/02/2007 | 3:15PM | PR Newswire (US) | FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension | NYSE:FRX | Forest Road Acquisition Corp |
| 11/29/2007 | 9:00AM | PR Newswire (US) | Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression | NYSE:FRX | Forest Road Acquisition Corp |
| 11/09/2007 | 4:05PM | Edgar (US Regulatory) | Forest Laboratories Inc - Quarterly Report (10-Q) | NYSE:FRX | Forest Road Acquisition Corp |
| 11/09/2007 | 4:05PM | Edgar (US Regulatory) | Forest Laboratories Inc - Quarterly Report (10-Q) | NYSE:FRX | Forest Road Acquisition Corp |
| 11/08/2007 | 8:30AM | PR Newswire (US) | Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show | NYSE:FRX | |
| 11/02/2007 | 2:10PM | PR Newswire (US) | Forest Laboratories and Cypress Bioscience to Host Webcast to Discuss Clinical Data Presentations for Milnacipran | NYSE:FRX | Forest Road Acquisition Corp |
| 11/01/2007 | 10:16AM | PR Newswire (US) | UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published i | NYSE:FRX | Forest Road Acquisition Corp |
| 11/01/2007 | 8:00AM | PR Newswire (US) | Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Jo | NYSE:FRX | Forest Road Acquisition Corp |
| 10/16/2007 | 8:05AM | PR Newswire (US) | Forest Laboratories Reports Earnings Per Share of $0.71 for Q2'08 Including $0.15 Charge Net of Tax for Licensing Charge | NYSE:FRX | Forest Road Acquisition Corp |
| 10/15/2007 | 4:10PM | PR Newswire (US) | Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia | NYSE:FRX | Forest Road Acquisition Corp |
| 10/12/2007 | 9:01AM | PR Newswire (US) | Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM) | NYSE:FRX | Forest Road Acquisition Corp |
| 10/08/2007 | 12:38PM | PR Newswire (US) | Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings | NYSE:FRX | Forest Road Acquisition Corp |
| 09/18/2007 | 6:05AM | PR Newswire (US) | Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress | NYSE:FRX | Forest Road Acquisition Corp |
| 09/17/2007 | 8:03AM | PR Newswire (US) | Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration | NYSE:FRX | Forest Road Acquisition Corp |
| 09/05/2007 | 12:24PM | PR Newswire (US) | Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision | NYSE:FRX | Forest Road Acquisition Corp |
| 09/04/2007 | 12:42PM | PR Newswire (US) | Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of | NYSE:FRX | Forest Road Acquisition Corp |
| 08/21/2007 | 7:58AM | PR Newswire (US) | Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM) | NYSE:FRX | Forest Road Acquisition Corp |
| 08/14/2007 | 6:01AM | Edgar (US Regulatory) | Forest Laboratories Inc - Securities Registration: Employee Benefit Plan | NYSE:FRX | Forest Road Acquisition Corp |
| 08/13/2007 | 2:39PM | PR Newswire (US) | Forest Laboratories, Inc. Expands Share Repurchase Program | NYSE:FRX | Forest Road Acquisition Corp |
| 07/17/2007 | 9:31AM | PR Newswire (US) | Seven Summits Research Releases Alerts on EBAY, MS, PEP, CFC, and FRX | NYSE:FRX | Forest Road Acquisition Corp |
| 07/17/2007 | 8:07AM | PR Newswire (US) | Forest Laboratories, Inc. Reports Fiscal First Quarter 2008 Earnings Per Share Of $0.83 | NYSE:FRX | Forest Road Acquisition Corp |
| 07/03/2007 | 3:27PM | PR Newswire (US) | Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 First Quarter Earnings | NYSE:FRX | Forest Road Acquisition Corp |
| 05/31/2007 | 5:15PM | PR Newswire (US) | Topline Results of Phase III Study in Acute Ischemic Stroke (Dias-2) Do Not Demonstrate Difference Between Desmoteplase and Plac | NYSE:FRX | Forest Road Acquisition Corp |
| 05/22/2007 | 5:56PM | PR Newswire (US) | Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatme | NYSE:FRX | Forest Road Acquisition Corp |
| 05/21/2007 | 9:00AM | PR Newswire (US) | Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy | NYSE:FRX | Forest Road Acquisition Corp |
| 05/01/2007 | 11:49AM | PR Newswire (US) | Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol | NYSE:FRX | |
| 04/24/2007 | 8:58AM | PR Newswire (US) | Forest Laboratories, Inc. Reports Fiscal Year 2007 Fourth Quarter Revenues of $885,000,000, Reported EPS Loss of ($0.75) and Adj | NYSE:FRX | Forest Road Acquisition Corp |
| 04/09/2007 | 4:30PM | PR Newswire (US) | Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2007 Fourth Quarter Earnings | NYSE:FRX | Forest Road Acquisition Corp |
| 02/12/2007 | 4:28PM | PR Newswire (US) | Forest Laboratories Announces Rule 144 Sale by Executive Officer | NYSE:FRX | Forest Road Acquisition Corp |
| 02/06/2007 | 5:30PM | PR Newswire (US) | Forest Laboratories Announces Termination of Agreement for Faropenem | NYSE:FRX | Forest Road Acquisition Corp |